PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON Russian patent published in 2024 - IPC A61K38/26 A61K38/28 A61K47/60 A61K47/68 A61P3/10 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to pharmaceutical industry, namely to a pharmaceutical combination, a composition for preventing or treating a disease associated with insulin. Pharmaceutical combination for preventing or treating a disease associated with insulin, containing insulin and glucagon, where insulin is associated with a biologically compatible substance capable of increasing its half-life in vivo, in the form of a long-acting conjugate and glucagon is bound to a biologically compatible substance capable of increasing its half-life in vivo, in the form of a long-acting conjugate, where the conjugate is represented by the following chemical formula 1: XL_a-F, where X is insulin or glucagon; L is polyethylene glycol; is 0 or a natural number, provided that when is 2 or more, each L is independent; F is an immunoglobulin Fc region capable of increasing the half-life of X in vivo; and "-" is a covalent or non-covalent bond, and wherein said combination contains insulin in the form of a long-acting conjugate and glucagon in the form of a long-acting conjugate in a weight ratio of 0.1:1 to 100:1. Pharmaceutical combination for preventing or treating hypoglycaemia, containing insulin and glucagon, where insulin is bound to a biologically compatible substance capable of increasing its half-life in vivo, in the form of a long-acting conjugate and glucagon is bound to a biologically compatible substance capable of increasing its half-life in vivo, in the form of a long-acting conjugate, where the conjugate is presented by chemical formula 1 (see above) and where said pharmaceutical combination contains insulin in the form of a long-acting conjugate and glucagon in the form of a long-acting conjugate in a weight ratio of 0.1:1 to 100:1. Combination for reducing the side effects of insulin, comprising insulin and glucagon, wherein the insulin is bound to a biologically compatible substance capable of increasing its half-life in vivo, in the form of a long-acting conjugate and glucagon is bound to a biologically compatible substance capable of increasing its half-life in vivo, in the form of a long-acting conjugate, where the conjugate is presented by chemical formula 1 (see above) and where said combination contains insulin in the form of a long-acting conjugate and glucagon in the form of a long-acting conjugate in a weight ratio of 0.1:1 to 100:1. Complex composition for reducing hypoglycaemia in a patient with an insulin-related disease, containing insulin and glucagon, where insulin is bound to a biologically compatible substance capable of increasing its half-life in vivo, in the form of a long-acting conjugate and glucagon is bound to a biologically compatible substance capable of increasing its half-life in vivo, in the form of a long-acting conjugate, where the conjugate is represented by chemical formula 1 (see above), and wherein said complex composition contains insulin in the form of a long-acting conjugate and glucagon in the form of a long-acting conjugate in a weight ratio of 0.1:1 to 100:1.

EFFECT: above-described combinations and composition effectively relieve hypoglycaemia, inhibit body weight gain, while providing a therapeutic effect on diseases associated with insulin, reduce side effects of the long-acting insulin conjugate.

39 cl, 3 dwg, 8 tbl, 11 ex